Saphnelo, a human monoclonal antibody, is a type 1 interferon (INF) receptor antagonist that inhibits a key protein in the immune system called the IFNAR receptor. This protein acts like a transmitter ...

A dairy farmer started feeling "overwhelming fatigue," but initially wrote off her symptoms as part of her "very physical" ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, for adults with systemic lupus erythematosus receiving standard therapy. The ...

Saphnelo (anifrolumab-fnia) is a prescription drug used to treat lupus. The drug can cause mild side effects including cough, sore throat, and upper respiratory infection or bronchitis. Serious side ...

People with lupus often need to use medicine to manage their symptoms. Although there are many oral medicines that treat lupus, some people with moderate to severe lupus may not get enough benefit ...

Saphnelo (anifrolumab-fnia) is a prescription drug used to treat systemic lupus erythematosus. The drug comes as an intravenous (IV) infusion. It’s usually given once every 4 weeks by a healthcare ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved AstraZeneca’s anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Saphnelo has not been studied in combination with other biologic therapies, including B-cell-targeted therapies such as Benlysta, and therefore is not recommended for use in combination with these ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...